Pharmacological and cell-specific genetic PI3Kα inhibition worsens cardiac remodeling after myocardial infarction
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacological and cell-specific genetic PI3Kα inhibition worsens cardiac remodeling after myocardial infarction
Authors
Keywords
Angiogenesis, Myocardial infarction, Myocardial remodeling, Signaling, PI3Kα
Journal
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
Volume 157, Issue -, Pages 17-30
Publisher
Elsevier BV
Online
2021-04-20
DOI
10.1016/j.yjmcc.2021.04.004
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cardiovascular toxicity of PI3Kα inhibitors
- (2020) Chandu Sadasivan et al. CLINICAL SCIENCE
- Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer
- (2019) Angela Esposito et al. JAMA Oncology
- A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)
- (2019) Ingrid A. Mayer et al. CLINICAL CANCER RESEARCH
- Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association
- (2019) Umberto Campia et al. CIRCULATION
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Disease and Cancer: Is There Increasing Overlap?
- (2019) Logan Vincent et al. Current Oncology Reports
- PI3Kα Pathway Inhibition With Doxorubicin Treatment Results in Distinct Biventricular Atrophy and Remodeling With Right Ventricular Dysfunction
- (2019) Brent A. McLean et al. Journal of the American Heart Association
- Inhibition of PI3Kinase-α is pro-arrhythmic and associated with enhanced late Na+ current, contractility, and Ca2+ release in murine hearts
- (2019) Pavel Zhabyeyev et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Apelin protects against abdominal aortic aneurysm and the therapeutic role of neutral endopeptidase resistant apelin analogs
- (2019) Wang Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities
- (2019) Jie Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Failing Heart Stimulates Tumor Growth by Circulating Factors
- (2018) Wouter C. Meijers et al. CIRCULATION
- Cell-Specific Functions of ADAM17 Regulate the Progression of Thoracic Aortic AneurysmNovelty and Significance
- (2018) Mengcheng Shen et al. CIRCULATION RESEARCH
- Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
- (2018) Dejan Juric et al. JOURNAL OF CLINICAL ONCOLOGY
- The PI3K/AKT pathway in obesity and type 2 diabetes
- (2018) Xingjun Huang et al. International Journal of Biological Sciences
- Targeted therapy in patients with PIK3CA-related overgrowth syndrome
- (2018) Quitterie Venot et al. NATURE
- Cancer-Associated PIK3CA Mutations in Overgrowth Disorders
- (2018) Ralitsa R. Madsen et al. TRENDS IN MOLECULAR MEDICINE
- A Phase 1 Study of Alpelisib (BYL719), an α- Specific PI3K Inhibitor, in Japanese Patients with Advanced Solid Tumors
- (2018) Yuichi Ando et al. CANCER SCIENCE
- Endothelial and cardiomyocyte PI3Kβ divergently regulate cardiac remodelling in response to ischaemic injury
- (2018) Xueyi Chen et al. CARDIOVASCULAR RESEARCH
- PI3Kα-regulated gelsolin activity is a critical determinant of cardiac cytoskeletal remodeling and heart disease
- (2018) Vaibhav B. Patel et al. Nature Communications
- Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer
- (2018) Dejan Juric et al. JAMA Oncology
- Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016
- (2017) Mohsen Naghavi et al. LANCET
- Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma
- (2017) Aviram Mizrachi et al. Nature Communications
- Relation of Muscle Mass and Fat Mass to Cardiovascular Disease Mortality
- (2016) Preethi Srikanthan et al. AMERICAN JOURNAL OF CARDIOLOGY
- Mesenchymal Stem Cells with eNOS Over-Expression Enhance Cardiac Repair in Rats with Myocardial Infarction
- (2016) Leilei Chen et al. CARDIOVASCULAR DRUGS AND THERAPY
- Shared Risk Factors in Cardiovascular Disease and Cancer
- (2016) Ryan J. Koene et al. CIRCULATION
- Cardio-Oncology
- (2016) Carrie G. Lenneman et al. CIRCULATION RESEARCH
- The Biological Basis for Cardiac Repair After Myocardial Infarction
- (2016) Sumanth D. Prabhu et al. CIRCULATION RESEARCH
- Heart Failure After Myocardial Infarction Is Associated With Increased Risk of Cancer
- (2016) Tal Hasin et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas
- (2015) Moshe Elkabets et al. CANCER CELL
- PI3Kα is essential for the recovery from Cre/tamoxifen cardiotoxicity and in myocardial insulin signalling but is not required for normal myocardial contractility in the adult heart
- (2015) Brent A. McLean et al. CARDIOVASCULAR RESEARCH
- Risk prediction of cardiovascular death based on the QTc interval: evaluating age and gender differences in a large primary care population
- (2014) J. B. Nielsen et al. EUROPEAN HEART JOURNAL
- BYL719, a new α-specific PI3K inhibitor: Single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma
- (2014) Bérengère Gobin et al. INTERNATIONAL JOURNAL OF CANCER
- Characterization of the Novel and Specific PI3K Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials
- (2014) C. Fritsch et al. MOLECULAR CANCER THERAPEUTICS
- Requirement for Interaction of PI3-Kinase p110α with RAS in Lung Tumor Maintenance
- (2013) Esther Castellano et al. CANCER CELL
- Loss of Apelin Exacerbates Myocardial Infarction Adverse Remodeling and Ischemia‐reperfusion Injury: Therapeutic Potential of Synthetic Apelin Analogues
- (2013) Wang Wang et al. Journal of the American Heart Association
- Exercise training and PI3Kα-induced electrical remodeling is independent of cellular hypertrophy and Akt signaling
- (2012) Kai-Chien Yang et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Enhanced recovery from ischemia–reperfusion injury in PI3Kα dominant negative hearts: Investigating the role of alternate PI3K isoforms, increased glucose oxidation and MAPK signaling
- (2012) Brent A. McLean et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- PI3K signalling: the path to discovery and understanding
- (2012) Bart Vanhaesebroeck et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Enhanced cardiac PI3Kα signalling mitigates arrhythmogenic electrical remodelling in pathological hypertrophy and heart failure
- (2011) Kai-Chien Yang et al. CARDIOVASCULAR RESEARCH
- Risk of coronary heart disease in patients with cancer: A nationwide follow-up study from Sweden
- (2011) Bengt Zöller et al. EUROPEAN JOURNAL OF CANCER
- Incidence and Risk of Congestive Heart Failure in Patients With Renal and Nonrenal Cell Carcinoma Treated With Sunitinib
- (2011) Christopher J. Richards et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration
- (2008) Mariona Graupera et al. NATURE
- The p110 isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110
- (2008) J. Guillermet-Guibert et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search